T1	Outcomes 152 198	safety, efficacy and imaging pharmacodynamics.
T2	Outcomes 738 742	arm.
T3	Outcomes 743 782	Exploratory pharmacodynamic assessments
T4	Outcomes 861 899	A, plasma AUC and C (max) of cediranib
T5	Outcomes 1032 1065	reduces cediranib plasma exposure
T6	Outcomes 1199 1234	with sustained antivascular effects
T7	Outcomes 1269 1308	reductions in DCE-MRI parameters and CT
T8	Outcomes 1416 1447	Evidence of antitumour activity
T9	Outcomes 1489 1529	effects upon imaging vascular parameters
